{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:15:19Z","timestamp":1762503319635,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T00:00:00Z","timestamp":1676764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ctro.2023.100603","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T23:34:51Z","timestamp":1677022491000},"page":"100603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT)"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-2072","authenticated-orcid":false,"given":"Trudy C.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-6810","authenticated-orcid":false,"given":"Ann C.","family":"Raldow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ctro.2023.100603_b0005","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2023.100603_b0010","unstructured":"pancreatic.pdf. Accessed July 26, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"issue":"10073","key":"10.1016\/j.ctro.2023.100603_b0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ctro.2023.100603_b0020","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctro.2023.100603_b0025","article-title":"Stereotactic versus conventional radiation therapy for patients with pancreatic cancer in the modern era","volume":"6","author":"Abi Jaoude","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2023.100603_b0030","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2023.100603_b0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijrobp.2020.11.017","article-title":"Maximizing tumor control and limiting complications with stereotactic body radiation therapy for pancreatic cancer","volume":"110","author":"Mahadevan","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100603_b0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"issue":"15_suppl","key":"10.1016\/j.ctro.2023.100603_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4505","volume":"38","author":"Ghaneh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctro.2023.100603_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4016","article-title":"Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial","volume":"39","author":"Van Eijck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100603_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctro.2023.100603_b0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS786","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for locally advanced pancreatic cancer","volume":"38","author":"Parikh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100603_b0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association","volume":"270","author":"Al-Hawary","year":"2014","journal-title":"Radiology"},{"issue":"3, Supplement","key":"10.1016\/j.ctro.2023.100603_b0070","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1016\/j.ijrobp.2015.07.884","article-title":"Stereotactic body radiation for pancreatic cancer: results of an international survey of practice patterns","volume":"93","author":"Parekh","year":"2015","journal-title":"Int J Radiat Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2023.100603_b0075","first-page":"e1618","article-title":"Online adaptive radiation therapy: implementation of a new process of care","volume":"9","author":"Lamb","year":"2017","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ctro.2023.100603_b0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.radonc.2018.08.009","article-title":"Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy","volume":"129","author":"Tyran","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2023.100603_b0085","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/j.prro.2020.01.012","article-title":"Dose-escalated radiation therapy for pancreatic cancer: a simultaneous integrated boost approach","volume":"10","author":"Koay","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100603_b0090","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100603_b0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2023.100603_b0100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"issue":"2, Supplement","key":"10.1016\/j.ctro.2023.100603_b0105","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1016\/j.ijrobp.2017.06.1042","article-title":"High dose adaptive MRI guided radiation therapy improves overall survival of inoperable pancreatic cancer","volume":"99","author":"Rudra","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100603_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat Oncol Lond Engl"},{"issue":"3","key":"10.1016\/j.ctro.2023.100603_b0115","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2008.01.051","article-title":"Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer","volume":"72","author":"Schellenberg","year":"2008","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2023.100603_b0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2023.100603_b0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.adro.2018.07.008","article-title":"Dose escalation for locally advanced pancreatic cancer: How high can we go?","volume":"3","author":"Colbert","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100603_b0130","unstructured":"Inc V. UCLA Health Treats its 1,000th Patient Using MRIdian\u00ae MRI-Guided Radiation Therapy. Accessed July 31, 2022. https:\/\/www.prnewswire.com\/news-releases\/ucla-health-treats-its-1-000th-patient-using-mridian-mri-guided-radiation-therapy-301356211.html."}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:12:49Z","timestamp":1762503169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630823000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"alternative-id":["S2405630823000289"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100603","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT)","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100603"}}